Skip Ribbon Commands
Skip to main content
CIBMTR

Study Lists

Sharing knowledge. Sharing Hope.
Skip Navigation LinksHome   /   Studies   /   Clinical Outcomes Research   /   Study Lists   /   Observational Studies
  • Print
  • Share

 


Plasma Cell Disorders Working Committee Studies

The Plasma Cell Disorders Working Committee provides scientific oversight for studies related to hematopoietic cell transplant and cellular therapy in multiple myeloma, light chain amyloidosis, and other plasma cell disorders.

Learn more about the studies conducted through the Plasma Cell Disorders Working Committee using the links below.

Recently Completed Studies

NumberTitleStatus
MM19-03 Second autologous stem cell transplantation as salvage therapy for relapsed or refractory immunoglobulin light chain amyloidosis. Published
MM19-02 Maintenance therapy after second autologous hematopoietic cell transplantation for multiple myeloma. Published
MM19-01 Impact of induction therapy with bortezomib, lenalidomide and dexamethasone vs. bortezomib, cyclophosphamide and dexamethasone on outcomes in patients with multiple myeloma undergoing stem cell transplantation. Published
MM18-04 Busulfan, melphalan, and bortezomib versus high-dose melphalan as a conditioning regimen for autologous transplants in multiple myeloma: Long term follow up of a novel conditioning regimen. Published
MM18-03b Transplant outcomes of elderly (>=75 years) multiple myeloma patients Published
MM18-03a To compare the outcomes in young patients with multiple myeloma at diagnosis (<50 years) undergoing autologous or allogeneic hematopoietic stem cell transplant with older patients (≥50): progression-free and overall survival in a case match. Published
MM18-02 Prognostic scoring system of outcomes in patients undergoing autologous stem cell transplantation for multiple myeloma. Published
MM18-01 Racial discrepancy in clinical outcomes of multiple myeloma patients harboring t(11;14) genetic abnormality. Published
MM17-02 The impact of bortezomib based induction therapy vs no induction therapy on outcomes for light chain amyloidosis. Published
MM17-01 Hematopoietic cell transplantation for primary plasma cell leukemia in the era of novel agents. Published

Last Updated: 10/22/2020 1:37 PM
CIBMTR